ZIGNEGO, ANNA LINDA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 33.580
EU - Europa 21.267
AS - Asia 13.438
SA - Sud America 1.590
AF - Africa 448
OC - Oceania 321
Continente sconosciuto - Info sul continente non disponibili 237
Totale 70.881
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 33.085
RU - Federazione Russa 7.128
IT - Italia 4.121
SG - Singapore 3.913
PL - Polonia 3.088
CN - Cina 2.573
HK - Hong Kong 2.370
IE - Irlanda 1.852
VN - Vietnam 1.502
SE - Svezia 1.452
BR - Brasile 1.298
KR - Corea 1.213
FI - Finlandia 851
UA - Ucraina 730
DE - Germania 706
FR - Francia 618
IN - India 463
TR - Turchia 380
GB - Regno Unito 359
AU - Australia 317
CA - Canada 296
JP - Giappone 294
CI - Costa d'Avorio 170
ID - Indonesia 123
BD - Bangladesh 119
AR - Argentina 105
IQ - Iraq 90
MX - Messico 79
NL - Olanda 72
JO - Giordania 70
ES - Italia 68
NG - Nigeria 67
ZA - Sudafrica 53
BE - Belgio 49
EC - Ecuador 45
PK - Pakistan 40
CO - Colombia 39
MA - Marocco 34
VE - Venezuela 34
AE - Emirati Arabi Uniti 33
CH - Svizzera 33
PH - Filippine 30
SA - Arabia Saudita 30
UZ - Uzbekistan 27
EG - Egitto 24
KE - Kenya 22
CZ - Repubblica Ceca 20
PY - Paraguay 20
SC - Seychelles 20
MY - Malesia 19
AZ - Azerbaigian 18
CL - Cile 18
JM - Giamaica 18
CR - Costa Rica 16
DZ - Algeria 16
LT - Lituania 14
TH - Thailandia 14
TT - Trinidad e Tobago 14
PE - Perù 13
RO - Romania 13
TW - Taiwan 13
IL - Israele 12
TN - Tunisia 12
UY - Uruguay 12
AT - Austria 11
BG - Bulgaria 11
DO - Repubblica Dominicana 11
HN - Honduras 10
PR - Porto Rico 10
AL - Albania 9
KG - Kirghizistan 9
KZ - Kazakistan 9
NP - Nepal 9
SY - Repubblica araba siriana 9
DK - Danimarca 8
EU - Europa 8
GT - Guatemala 8
PT - Portogallo 8
ET - Etiopia 7
PA - Panama 7
AM - Armenia 6
BH - Bahrain 6
HU - Ungheria 6
PS - Palestinian Territory 6
SN - Senegal 6
BO - Bolivia 5
BY - Bielorussia 5
LV - Lettonia 5
OM - Oman 5
SV - El Salvador 5
BB - Barbados 4
GE - Georgia 4
GR - Grecia 4
IR - Iran 4
KH - Cambogia 4
MM - Myanmar 4
NO - Norvegia 4
RS - Serbia 4
SK - Slovacchia (Repubblica Slovacca) 4
AO - Angola 3
Totale 70.585
Salva come PNG Salva come JPEG
Città #
Santa Clara 6.395
Warsaw 3.071
Ashburn 2.932
Singapore 2.694
Fairfield 2.633
Hong Kong 1.892
Dublin 1.849
Chandler 1.762
San Jose 1.523
Seoul 1.179
Woodbridge 1.163
Cambridge 1.092
Seattle 1.062
Jacksonville 1.018
Wilmington 957
Houston 930
Milan 871
Beijing 671
The Dalles 613
Princeton 565
Buffalo 522
Altamura 481
Ann Arbor 463
Lauterbourg 456
Ho Chi Minh City 452
Lawrence 437
Los Angeles 412
Boston 380
Rome 375
Hefei 333
Boardman 330
Mumbai 322
Hanoi 320
Helsinki 307
Melbourne 305
Florence 301
Tokyo 281
Medford 271
Izmir 260
Moscow 218
Council Bluffs 176
Dallas 174
Abidjan 170
New York 153
San Diego 148
Norwalk 145
Munich 134
Shanghai 134
Dong Ket 118
Falls Church 114
Naples 104
São Paulo 102
Sunnyvale 92
Jakarta 84
Toronto 83
Redondo Beach 81
Turin 81
Bremen 80
Frankfurt am Main 76
Figino 75
Bologna 73
Clifton 71
Hillsboro 68
Abuja 65
Da Nang 64
Paris 58
London 56
Andover 55
Turku 54
Dearborn 53
Verona 51
Palermo 50
Montreal 48
Haiphong 47
Brussels 46
Chicago 45
Kent 44
Guangzhou 42
Istanbul 41
Orem 41
Washington 40
Bari 38
Genoa 37
Miano 37
Brooklyn 36
Phoenix 36
Atlanta 32
Frankfurt Am Main 32
Salerno 32
Venice 32
Baghdad 30
Redmond 30
West Jordan 30
Bern 29
Brescia 29
Rio de Janeiro 29
Yubileyny 29
Auburn Hills 28
Johannesburg 28
Tashkent 27
Totale 46.135
Salva come PNG Salva come JPEG
Nome #
Serum hepatitis delta virus RNA in patients with delta hepatitis and in liver graft recipients 1.202
Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel 378
Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis 375
Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection 352
Hepatitis C Virus infection in the immunocompromised host: a complex scenario with variable clinical impact 334
Evaluation of the prognostic value of liver stiffness in patients with hepatitis C virus treated with triple or dual antiviral therapy: A prospective pilot study 323
Role of MicroRNA Profile Modifications in Hepatitis C Virus-Related Mixed Cryoglobulinemia 319
Assessment of liver stiffness in patients with HCV and mixed cryoglobulinemia undergoing rituximab treatment. 303
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network 301
Strategie terapeutiche nella crioglobulinemia mista: recenti acquisizioni 293
HCV and lymphoproliferation 282
Hepatitis C virus infection and arthritis. A clinico-serological investigation of arthritis in patients with or without cryoglobulinemic syndrome 279
Identification of new autoantigens by protein array indicates a role for IL4 neutralization in Autoimmune Hepatitis 274
Liver cancer-derived hepatitis C virus core proteins shift TGF-beta responses from tumor suppression to epithelial-mesenchymal transition 272
Notch4 and mhc class II polymorphisms are associated with hcv-related benign and malignant lymphoproliferative diseases 270
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 267
Impact of immunogenetic IL28B polymorphism on natural outcome of HCV infection. 264
Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study 263
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 263
Individualized treatment of genotype 1 naïve patients: an Italian multicenter field practice experience. 262
HCV Patients Psychopathology and Tryptophan Metabolism: Analysis of the Effects of Pegylated Interferon plus Ribavirin Treatment 259
Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: Phase II clinical trial and systematic review 257
Assessment of free light chains in HCV-positive patients with mixed cryoglobulinaemia vasculitis undergoing rituximab treatment 256
A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection 255
Mixed cryoglobulinemia, lymphomas and HCV 246
Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals? 244
The metabolic fingerprints of HCV and HBV infections studied by Nuclear Magnetic Resonance Spectroscopy 242
Genetic diversity of the KIR/HLA system and susceptibility to hepatitis C virus-related diseases 239
Retreatment regimen of rituximab monotherapy given at the relapse of severe HCV-related cryoglobulinemic vasculitis: Long-term follow up data of a randomized controlled multicentre study 237
HCV-related liver and lymphoproliferative diseases: Association with polymorphisms of IL28B and TLR2 234
Autoimmunity and lymphoproliferation markers in naïve HCV-RNA positive patients without clinical evidences of autoimmune/lymphoproliferative disorders 234
Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia 234
Interferon-free therapy in hepatitis C virus mixed cryoglobulinaemia: a prospective, controlled, clinical and quality of life analysis 231
Combined treatment with antiviral therapy and rituximab in patients with mixed cryoglobulinemia: review of the literature and report of a case using direct antiviral agents-based antihepatitis C virus therapy 230
International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement 229
Deregulation of microRNA expression in peripheral blood mononuclear cells from patients with HCV-related malignancies 229
Amplification of hepatitis delta virus RNA sequences by polymerase chain reaction: a tool for viral detection and cloning 227
Longitudinal assessment of liver stiffness in patients undergoing antiviral treatment for hepatitis C 226
Effect of antiviral treatment in patients with chronic HCV infection and t(14;18) translocation 221
B-cells and mixed cryoglobulinemia 221
Longitudinal evaluation of liver stiffness and outcomes in patients with chronic hepatitis C before and after short- and long-term IFN-free antiviral treatment 221
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 221
AISF position paper on liver transplantation and pregnancy: Women in Hepatology Group, Italian Association for the Study of the Liver (AISF) 220
Impact of safety-related dose reductions or discontinuations on sustained virologic response in HCV-infected patients: Results from the GUARD-C Cohort 220
Clinical significance of polymorphisms in immune response genes in hepatitis C-related hepatocellular carcinoma 219
AISF position paper on HCV in immunocompromised patients 217
Association Between Persistent Lymphatic Infection By Hepatitis C Virus After Antiviral Treatment And Mixed Cryoglobulinemia 216
"Inapparent" hepatitis B virus infection and hepatitis C virus replication in alcoholic subjects with and without liver disease 216
Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1 216
Current and future challenges in HCV: insights from an Italian experts panel 215
Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN) 212
Hepatitis B virus related cryoglobulinemic vasculitis: A multicentre open label study from the Gruppo Italiano di Studio delle Crioglobulinemie - GISC 212
A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3 211
Effect of chronic hepatitis C virus infection on inflammatory lipid mediators 209
Host genetic determinants in HCV-related mixed cryoglobulinemia 206
IgG3 subclass: A possible trigger of mixed cryoglobulin cascade in hepatitis C virus chronic infection 206
Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: A prospective, controlled, open-label, cohort study. 205
Treatment of HCV-related mixed cryoglobulinemia 202
Epidemiological, demographic and clinical data on chronic viral hepatitis C in Tuscany 201
Clinical epidemiology of chronic viral hepatitis B: A Tuscany real-word large-scale cohort study 201
Hepatitis C virus in mixed cryoglobulinemia and B cell lymphoma 200
International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement 199
Host genetic determinants in HCV-related mixed cryoglobulinemia 198
Modifications of plasma platelet-activating factor (PAF)- acetylhydrolase/PAF system activity in patients with chronic hepatitis C virus infection 196
Real life experiences in HCV management in 2018 194
From current status to optimization of HCV treatment: Recommendations from an expert panel 194
MicroRNA expression in hepatitis C virus-related malignancies: A brief review 193
Combined presence of HCVRNA sequences and t(14;18) (q32;q21) translocation in PBMC from patients with chronic HCV infection 192
Hepatitis C virus syndrome: A constellation of organ- and non-organ specific autoimmune disorders, B-cell non- Hodgkin's lymphoma, and cancer 192
Association between mixed cryoglobulinemia, translocation (14;18), and persistence of occult HCV lymphoid infection after treatment 192
Hepatocellular carcinoma in mixed cryoglobulinemia patients 191
Non-invasive assessment of liver fibrosis in patients with HBV-related chronic liver disease undergoing antiviral treatment: A preliminary study 191
A novel biomarker score for the screening and management of patients with plasma cell proliferative disorders 191
Analysis of HCV persistence in patients with sustained virological response 190
Chronic hepatitis C and B-cell non-Hodgkin's lymphoma 189
Modeling cost-effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real-life cohort 188
CD81 Modulation by Immobilized Monoclonal Antibodies is Able to Promote B-cell proliferation and C-MYC expression 187
Hepatitis C virus-related mixed cryoglobulinemia: is genetics to blame? 186
COMBINED PRESENCE OF HCVRNA SEQUENCES AND T(14;18) (q32;q21) TRANSLOCATION IN PBMC FROM PATIENTS WITH CHRONIC HCV INFECTION. 185
Hematological and Genetic Markers in the Rational Approach to Patients With HCV Sustained Virological Response With or Without Persisting Cryoglobulinemic Vasculitis 185
Sentinel biomarkers in HCV positive patients with mixed cryoglobulinemia 184
MR-diffusion imaging in assessing chronic liver diseases: does a clinical role exist? 184
Infection of peripheral mononuclear blood cells by hepatitis C virus 183
The Italian compassionate use of sofosbuvir observational cohort study for the treatment of recurrent hepatitis C: clinical and virological outcomes 183
Longitudinal assessment of liver stiffness in patients undergoing antiviral treatment for hepatitis C. 182
Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: A prospective, controlled pilot study. 180
Different metabolic fingerprints between HCV and HBV patients: a possible interference of the two major hepatitis viruses in basal metabolism pathways. 179
Interferon and thymosin combination therapy in naive patients with chronic hepatitis C. Preliminary results 177
Improvement in liver cirrhosis after treatment of HCV-related mixed cryoglobulinemia with rituximab 177
Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease 176
HCV-related mixed cryoglobulinemia and BAFF promoter polymorphism 176
CD81 modulation by immobilized monoclonal antibodies is able to promote B-cell proliferation and c-myc expression 176
Low serum tryptophan levels, reduced macrophage IDO activity and high frequency of psychopathology in HCV patients 175
Can BAFF promoter polymorphism be a predisposing condition for HCV-related mixed cryoglobulinemia? 175
Hepatitis C virus genotype analysis in patients with type II mixed cryoglobulinemia 175
Direct medical costs associated with the extrahepatic manifestations of hepatitis C infection in Europe 174
microRNA PROFILE MODIFICATIONS IN HEPATITIS C VIRUS-RELATED MIXED CRYOGLOBULINEMIA 174
Hepatitis C virus-related autoimmunity in patients with porphyria cutanea tarda 173
CD81 MODULATION BY IMMOBILIZED MONOCLONAL ANTIBODIES IS ABLE TO PROMOTE B-CELL PROLIFERATION AND C-MYC EXPRESSION 172
Anti-TNF-α therapy prevents the recurrence of joint bleeding in haemophilia and arthritis 172
Totale 23.253
Salva come PNG Salva come JPEG
Categoria #
all - tutte 197.203
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 197.203
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20223.236 0 397 150 154 112 129 109 212 120 98 543 1.212
2022/20237.696 875 1.073 303 535 729 1.661 964 385 770 49 239 113
2023/20242.265 142 390 574 119 143 269 35 368 36 70 61 58
2024/202518.782 711 2.158 1.388 2.815 5.866 1.983 197 1.035 1.191 406 560 472
2025/202620.934 2.175 2.832 1.356 1.199 1.975 849 2.714 1.120 1.929 1.289 524 2.972
2026/2027863 540 323 0 0 0 0 0 0 0 0 0 0
Totale 70.881